

Global Live Attenuated Influenza Vaccine (LAIV) Market Research Report 2026(Status and Outlook)

<https://marketpublishers.com/r/G9E44EDAD622EN.html>

Date: February 2026

Pages: 153

Price: US\$ 2,980.00 (Single User License)

ID: G9E44EDAD622EN

Abstracts

A Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" or "intranasal" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.

Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts.

Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations.

Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccine's effectiveness is crucial in maintaining public confidence and its role in influenza prevention.

Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccine's effectiveness.

Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use.

The global Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 8569.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.30% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Live Attenuated Influenza Vaccine (LAIV) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Live Attenuated Influenza Vaccine (LAIV) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Live Attenuated Influenza Vaccine (LAIV) market.

Global Live Attenuated Influenza Vaccine (LAIV) Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology

Market Segmentation (by Type)

Trivalent Flu Vaccine
Quadrivalent Flu Vaccine

Market Segmentation (by Application)

Hospital
Clinic
Public Health Agency
Other

Geographic Segmentation

North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance

Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Live Attenuated Influenza Vaccine (LAIV) Market
Overview of the regional outlook of the Live Attenuated Influenza Vaccine (LAIV) Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine (LAIV) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine (LAIV), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players,

along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Live Attenuated Influenza Vaccine (LAIV)

1.2 Key Market Segments

1.2.1 Live Attenuated Influenza Vaccine (LAIV) Segment by Type

1.2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Estimates and Forecasts (2020-2035)

2.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts (2020-2035)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant

3.2 Global Live Attenuated Influenza Vaccine (LAIV) Product Life Cycle

3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2020-2025)

3.4 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2020-2025)

3.5 Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2020-2025)

3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types

3.8 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends

3.8.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate

3.8.2 Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players

Market Share by Revenue

3.8.3 Mergers & Acquisitions, Expansion

4 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) INDUSTRY CHAIN ANALYSIS

4.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Industry News

5.4.1 New Product Developments

5.4.2 Mergers & Acquisitions

5.4.3 Expansions

5.4.4 Collaboration/Supply Contracts

5.5 PEST Analysis

5.5.1 Industry Policies Analysis

5.5.2 Economic Environment Analysis

5.5.3 Social Environment Analysis

5.5.4 Technological Environment Analysis

5.6 Global Live Attenuated Influenza Vaccine (LAIV) Market Porter's Five Forces Analysis

5.6.1 Global Trade Frictions

5.6.2 U.S. Tariff Policy ? April 2025

5.6.3 Global Trade Frictions and Their Impacts to Live Attenuated Influenza Vaccine (LAIV) Market

5.7 ESG Ratings of Leading Companies

6 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2020-2025)
- 6.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (2020-2025)
- 6.4 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2020-2025)

7 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Sales by Application (2020-2025)
- 7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Application (2020-2025)
- 7.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)

8 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SALES BY REGION

- 8.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
 - 8.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
 - 8.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region
- 8.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
 - 8.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
 - 8.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
- 8.3 North America
 - 8.3.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
 - 8.3.2 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
 - 8.3.3 U.S. Market Overview
 - 8.3.4 Canada Market Overview
 - 8.3.5 Mexico Market Overview
- 8.4 Europe
 - 8.4.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country
 - 8.4.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
 - 8.4.3 Germany Market Overview
 - 8.4.4 France Market Overview
 - 8.4.5 U.K. Market Overview
 - 8.4.6 Italy Market Overview

8.4.7 Spain Market Overview

8.5 Asia Pacific

8.5.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region

8.5.2 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region

8.5.3 China Market Overview

8.5.4 Japan Market Overview

8.5.5 South Korea Market Overview

8.5.6 India Market Overview

8.5.7 Southeast Asia Market Overview

8.6 South America

8.6.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country

8.6.2 South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country

8.6.3 Brazil Market Overview

8.6.4 Argentina Market Overview

8.6.5 Columbia Market Overview

8.7 Middle East and Africa

8.7.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region

8.7.2 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region

8.7.3 Saudi Arabia Market Overview

8.7.4 UAE Market Overview

8.7.5 Egypt Market Overview

8.7.6 Nigeria Market Overview

8.7.7 South Africa Market Overview

9 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET PRODUCTION BY REGION

9.1 Global Production of Live Attenuated Influenza Vaccine (LAIV) by Region(2020-2025)

9.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2020-2025)

9.3 Global Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)

9.4 North America Live Attenuated Influenza Vaccine (LAIV) Production

9.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)

9.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Production, Revenue,

Price and Gross Margin (2020-2025)

9.5 Europe Live Attenuated Influenza Vaccine (LAIV) Production

9.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)

9.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)

9.6 Japan Live Attenuated Influenza Vaccine (LAIV) Production (2020-2025)

9.6.1 Japan Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)

9.6.2 Japan Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)

9.7 China Live Attenuated Influenza Vaccine (LAIV) Production (2020-2025)

9.7.1 China Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2020-2025)

9.7.2 China Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Sanofi Pasteur

10.1.1 Sanofi Pasteur Basic Information

10.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Market Performance

10.1.4 Sanofi Pasteur Business Overview

10.1.5 Sanofi Pasteur SWOT Analysis

10.1.6 Sanofi Pasteur Recent Developments

10.2 AstraZeneca

10.2.1 AstraZeneca Basic Information

10.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Market Performance

10.2.4 AstraZeneca Business Overview

10.2.5 AstraZeneca SWOT Analysis

10.2.6 AstraZeneca Recent Developments

10.3 CSL

10.3.1 CSL Basic Information

10.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product Market Performance

- 10.3.4 CSL Business Overview
- 10.3.5 CSL SWOT Analysis
- 10.3.6 CSL Recent Developments
- 10.4 Abbott
 - 10.4.1 Abbott Basic Information
 - 10.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.4.4 Abbott Business Overview
 - 10.4.5 Abbott Recent Developments
- 10.5 GlaxoSmithKline
 - 10.5.1 GlaxoSmithKline Basic Information
 - 10.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.5.4 GlaxoSmithKline Business Overview
 - 10.5.5 GlaxoSmithKline Recent Developments
- 10.6 Serum Institute
 - 10.6.1 Serum Institute Basic Information
 - 10.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.6.4 Serum Institute Business Overview
 - 10.6.5 Serum Institute Recent Developments
- 10.7 Fluenz Tetra
 - 10.7.1 Fluenz Tetra Basic Information
 - 10.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.7.4 Fluenz Tetra Business Overview
 - 10.7.5 Fluenz Tetra Recent Developments
- 10.8 Cytiva
 - 10.8.1 Cytiva Basic Information
 - 10.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.8.4 Cytiva Business Overview
 - 10.8.5 Cytiva Recent Developments
- 10.9 BioDiem
 - 10.9.1 BioDiem Basic Information
 - 10.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview

- 10.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
- 10.9.4 BioDiem Business Overview
- 10.9.5 BioDiem Recent Developments
- 10.10 FluMist
 - 10.10.1 FluMist Basic Information
 - 10.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.10.4 FluMist Business Overview
 - 10.10.5 FluMist Recent Developments
- 10.11 GSK
 - 10.11.1 GSK Basic Information
 - 10.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.11.4 GSK Business Overview
 - 10.11.5 GSK Recent Developments
- 10.12 ChangChun High and New Technology
 - 10.12.1 ChangChun High and New Technology Basic Information
 - 10.12.2 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.12.3 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.12.4 ChangChun High and New Technology Business Overview
 - 10.12.5 ChangChun High and New Technology Recent Developments
- 10.13 BCHT Biotechnology
 - 10.13.1 BCHT Biotechnology Basic Information
 - 10.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.13.4 BCHT Biotechnology Business Overview
 - 10.13.5 BCHT Biotechnology Recent Developments

11 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET FORECAST BY REGION

- 11.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast
- 11.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by

Country

11.2.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region

11.2.4 South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Type (2026-2035)

12.1.1 Global Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Type (2026-2035)

12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2026-2035)

12.1.3 Global Forecasted Price of Live Attenuated Influenza Vaccine (LAIV) by Type (2026-2035)

12.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Application (2026-2035)

12.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application

12.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)

Table 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application

Table 5. Live Attenuated Influenza Vaccine (LAIV) Market Size Comparison by Region (M USD)

Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Manufacturers (2020-2025)

Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2020-2025)

Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (M USD) by Manufacturers (2020-2025)

Table 9. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2020-2025)

Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2025)

Table 11. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/KG) of Key Manufacturers (2020-2025)

Table 12. Manufacturers? Manufacturing Sites, Areas Served

Table 13. Manufacturers? Product Type

Table 14. Global Live Attenuated Influenza Vaccine (LAIV) Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Live Attenuated Influenza Vaccine (LAIV) Market Challenges

Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026

Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027

Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026

Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries

Table 26. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (K MT)

Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)

Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Type (2020-2025)

Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2020-2025)

Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Type (2020-2025)

Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type (2020-2025)

Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Price (USD/KG) by Type (2020-2025)

Table 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Application

Table 34. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application

Table 35. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2020-2025) & (K MT)

Table 36. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2020-2025)

Table 37. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application (2020-2025) & (M USD)

Table 38. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2020-2025)

Table 39. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)

Table 40. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2020-2025) & (K MT)

Table 41. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2020-2025)

Table 42. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025) & (M USD)

Table 43. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025)

Table 44. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)

Table 45. North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (2020-2025) & (M USD)

Table 46. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2020-2025) & (K MT)

Table 47. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country

(2020-2025) & (M USD)

Table 48. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region

(2020-2025) & (K MT)

Table 49. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region

(2020-2025) & (M USD)

Table 50. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country

(2020-2025) & (K MT)

Table 51. South America Live Attenuated Influenza Vaccine (LAIV) Market Size by

Country (2020-2025) & (M USD)

Table 52. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by

Region (2020-2025) & (K MT)

Table 53. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size

by Region (2020-2025) & (M USD)

Table 54. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT) by

Region(2020-2025)

Table 55. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US\$ Million) by

Region (2020-2025)

Table 56. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by

Region (2020-2025)

Table 57. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue

(US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 58. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT),

Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 59. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT),

Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 60. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue

(US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 61. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue

(US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 62. Sanofi Pasteur Basic Information

Table 63. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 64. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K MT),

Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 65. Sanofi Pasteur Business Overview

Table 66. Sanofi Pasteur SWOT Analysis

Table 67. Sanofi Pasteur Recent Developments

Table 68. AstraZeneca Basic Information

Table 69. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 70. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K MT),

Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 71. AstraZeneca Business Overview

Table 72. AstraZeneca SWOT Analysis

Table 73. AstraZeneca Recent Developments

Table 74. CSL Basic Information

Table 75. CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 76. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 77. CSL Business Overview

Table 78. CSL SWOT Analysis

Table 79. CSL Recent Developments

Table 80. Abbott Basic Information

Table 81. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 82. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 83. Abbott Business Overview

Table 84. Abbott Recent Developments

Table 85. GlaxoSmithKline Basic Information

Table 86. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 87. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 88. GlaxoSmithKline Business Overview

Table 89. GlaxoSmithKline Recent Developments

Table 90. Serum Institute Basic Information

Table 91. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 92. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 93. Serum Institute Business Overview

Table 94. Serum Institute Recent Developments

Table 95. Fluenz Tetra Basic Information

Table 96. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 97. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 98. Fluenz Tetra Business Overview

Table 99. Fluenz Tetra Recent Developments

Table 100. Cytiva Basic Information

Table 101. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 102. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 103. Cytiva Business Overview

Table 104. Cytiva Recent Developments

Table 105. BioDiem Basic Information

Table 106. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 107. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 108. BioDiem Business Overview

Table 109. BioDiem Recent Developments

Table 110. FluMist Basic Information

Table 111. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 112. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 113. FluMist Business Overview

Table 114. FluMist Recent Developments

Table 115. GSK Basic Information

Table 116. GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 117. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 118. GSK Business Overview

Table 119. GSK Recent Developments

Table 120. ChangChun High and New Technology Basic Information

Table 121. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 122. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 123. ChangChun High and New Technology Business Overview

Table 124. ChangChun High and New Technology Recent Developments

Table 125. BCHT Biotechnology Basic Information

Table 126. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 127. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 128. BCHT Biotechnology Business Overview

Table 129. BCHT Biotechnology Recent Developments

Table 130. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2026-2035) & (K MT)

Table 131. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2026-2035) & (M USD)

Table 132. North America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)

Table 133. North America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)

Table 134. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)

Table 135. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)

Table 136. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2026-2035) & (K MT)

Table 137. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2026-2035) & (M USD)

Table 138. South America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (K MT)

Table 139. South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)

Table 140. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2026-2035) & (Units)

Table 141. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2026-2035) & (M USD)

Table 142. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Type (2026-2035) & (K MT)

Table 143. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2026-2035) & (M USD)

Table 144. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type (2026-2035) & (USD/KG)

Table 145. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application (2026-2035)

Table 146. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD), 2025-2035
- Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) (2020-2035)
- Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) & (2020-2035)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Product Life Cycle
- Figure 13. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2025
- Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2025
- Figure 15. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
- Figure 16. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/KG) of Key Manufacturers in 2025
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2025
- Figure 18. Industry Chain Map of Live Attenuated Influenza Vaccine (LAIV)
- Figure 19. Global Live Attenuated Influenza Vaccine (LAIV) Market PEST Analysis
- Figure 20. Global Live Attenuated Influenza Vaccine (LAIV) Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type
- Figure 27. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type

(2020-2025)

Figure 28. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2025

Figure 29. Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2020-2025)

Figure 30. Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2025

Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 32. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application

Figure 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2020-2025)

Figure 34. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application in 2025

Figure 35. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2020-2025)

Figure 36. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2025

Figure 37. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2020-2025)

Figure 38. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2020-2025)

Figure 39. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (2020-2025)

Figure 40. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 41. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 42. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024

Figure 43. North America Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 44. North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024

Figure 45. U.S. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 46. U.S. Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. Canada Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) and Growth Rate (2020-2025)

Figure 48. Canada Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) and

Growth Rate (2020-2025)

Figure 49. Mexico Live Attenuated Influenza Vaccine (LAIV) Sales (Units) and Growth Rate (2020-2025)

Figure 50. Mexico Live Attenuated Influenza Vaccine (LAIV) Market Size (Units) and Growth Rate (2020-2025)

Figure 51. Europe Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 52. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024

Figure 53. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024

Figure 55. Germany Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)

Figure 66. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2024

Figure 67. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region in 2024

Figure 68. China Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 73. South Korea Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 75. India Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 78. South America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)

Figure 79. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2024

Figure 80. South America Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (M USD)

Figure 81. South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country in 2024

Figure 82. Brazil Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 83. Brazil Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 84. Argentina Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 85. Argentina Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 86. Columbia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 87. Columbia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth

Rate (2020-2025) & (M USD)

Figure 88. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)

Figure 89. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2024

Figure 90. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (M USD)

Figure 91. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Region in 2024

Figure 92. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 93. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 94. UAE Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 95. UAE Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 96. Egypt Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 97. Egypt Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 98. Nigeria Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 99. Nigeria Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 100. South Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2020-2025) & (K MT)

Figure 101. South Africa Live Attenuated Influenza Vaccine (LAIV) Market Size and Growth Rate (2020-2025) & (M USD)

Figure 102. Global Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2020-2025)

Figure 103. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)

Figure 104. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)

Figure 105. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)

Figure 106. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2020-2025)

Figure 107. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Volume (2020-2035) & (K MT)

Figure 108. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Value (2020-2035) & (M USD)

Figure 109. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Type (2026-2035)

Figure 110. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Type (2026-2035)

Figure 111. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Application (2026-2035)

Figure 112. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Application (2026-2035)

I would like to order

Product name: Global Live Attenuated Influenza Vaccine (LAIV) Market Research Report 2026(Status and Outlook)

Product link: <https://marketpublishers.com/r/G9E44EDAD622EN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9E44EDAD622EN.html>